SUPRIYA
Supriya Lifescience Limited
NSE BSELast Traded Price
₹628.1
-22.85 (-3.51%)
Open
₹661.75
High
₹661.75
Low
₹598.05
Prev Close
₹650.95
Industry
Pharmaceuticals
Market Cap
5080.48 Cr
Filing History
Recent corporate announcements and filings for SUPRIYA
Business Update
Neutral
2026-11-06 19:34
- Supriya Lifescience Ltd informed the exchanges about the availability of the audio recording of the Earnings Call held on November 6, 2026.
- The call discussed the operational and financial performance for the quarter and half year ended September 30, 2026.
- The audio recording has been made available on the company's official website.
Business Update
Neutral
2026-11-06 19:23
- Supriya Lifescience Limited informed the exchange regarding the availability of the audio recording of the Earnings Call held on November 6, 2026.
- The call discussed the operational and financial performance for the quarter and half year ended September 30, 2026.
- The audio recording can be accessed on the company's website.
Financials
Neutral
2026-11-06 19:22
Q2 FY27 Consolidated Revenue ₹206.30Cr vs ₹199.83Cr (▲3.2% YoY)
EBITDA ₹45.40Cr vs ₹72.65Cr (▼37.5% YoY)
PAT ₹29.25Cr vs ₹50.43Cr (▼42.0% YoY)
EBITDA Margin 22.0% vs 36.4% (▼1440bps)
Financials
Negative
2026-11-06 19:11
Q2 FY27 Consolidated Revenue ₹206.30Cr vs ₹199.83Cr (▲3.2% YoY)
EBITDA ₹45.40Cr vs ₹72.65Cr (▼37.5% YoY)
PAT ₹29.25Cr vs ₹50.43Cr (▼42.0% YoY)
EBITDA Margin 22.0% vs 36.4% (▼1440bps)
Business Update
Neutral
2026-11-06 13:28
- Supriya Lifescience released its Q2 & H1 FY27 investor presentation.
- Q2 FY27 Revenue grew 3.2% YoY to ₹2,063.0 Mn.
- Q2 FY27 EBITDA declined 37.5% YoY to ₹454.0 Mn with EBITDA margin at 22.0% (down 1,435 bps YoY).
- Q2 FY27 PAT dropped 42.0% YoY to ₹292.5 Mn.
Business Update
Neutral
2026-11-06 13:26
- Q2 FY27 Revenue grew 3.2% YoY to ₹2,063 Mn.
- EBITDA declined 37.5% YoY to ₹454 Mn; margin contracted to 22.0% from 36.4% YoY.
- PAT dropped 42.0% YoY to ₹292.5 Mn.
- Key revenue contributors: Europe (43%) and Asia (36%).
Financials
Neutral
2026-11-06 13:23
Q2 FY27 Standalone Revenue ₹206.30Cr vs ₹199.83Cr (▲3.2% YoY)
EBITDA ₹45.40Cr vs ₹72.65Cr (▼37.5% YoY)
PAT ₹29.25Cr vs ₹50.43Cr (▼42.0% YoY)
EBITDA Margin 22.01% vs 36.35% (▼1434bps)
Financials
Neutral
2026-11-06 13:22
Q2 FY27 Standalone Revenue ₹206.30Cr vs ₹199.83Cr (▲3.2% YoY)
EBITDA ₹45.40Cr vs ₹72.65Cr (▼37.5% YoY)
PAT ₹29.25Cr vs ₹50.43Cr (▼42.0% YoY)
EBITDA Margin 22.01% vs 36.35% (▼1434bps)
Financials
Neutral
2026-11-06 13:06
Q2 FY27 Standalone Revenue ₹206.30 Cr vs ₹199.83 Cr (▲3.2% YoY)
EBITDA ₹45.40 Cr vs ₹72.65 Cr (▼37.5% YoY)
PAT ₹29.25 Cr vs ₹50.43 Cr (▼42.0% YoY)
EBITDA Margin 22.01% vs 36.35% (▼1434bps)
Financials
Neutral
2026-11-06 13:00
Q2 FY27 Standalone Revenue ₹206.30Cr vs ₹199.83Cr (▲3.2% YoY)
EBITDA ₹45.40Cr vs ₹72.65Cr (▼37.5% YoY)
PAT ₹29.25Cr vs ₹50.43Cr (▼42.0% YoY)
EBITDA Margin 22.01% vs 36.35% (▼1434bps)
- Appointed Mr. Mangesh Vaze as Chief Operating Officer (COO) and Senior Management Personnel.
Financials
Neutral
2026-11-06 12:57
- Supriya Lifescience Limited submitted financial results for the period ended September 30, 2026.
- Detailed financial statement figures were not included in the text.
Financials
Neutral
2026-11-06 12:52
Q2 FY27 Standalone Revenue ₹206.30Cr vs ₹199.83Cr (▲3.2% YoY)
EBITDA ₹45.40Cr vs ₹72.65Cr (▼37.5% YoY)
PAT ₹29.25Cr vs ₹50.43Cr (▼42.0% YoY)
EBITDA Margin 22.0% vs 36.4% (▼1434bps)
Appointed Mr. Mangesh Vaze as Chief Operating Officer and Senior Management Personnel effective November 6, 2026
Governance
Negative
2026-11-02 21:15
CRITICAL RED FLAG DETECTED
- Mr. Sreekant Sreedharan, General Manager – Sales & Marketing of Supriya Lifescience Limited, has been granted bail from the sessions court on November 2, 2026.
- The matter pertains to judicial proceedings under the Narcotic Drugs and Psychotropic Substances Act, 1985.
- The company stated that the order does not have a material impact on the entity.
Governance
Negative
2026-11-02 21:13
CRITICAL RED FLAG DETECTED
- Mr. Sreekant Sreedharan, General Manager – Sales & Marketing of Supriya Lifescience Ltd, has been granted bail from the sessions court in judicial proceedings under the NDPS Act, 1985 on November 2, 2026.
- The company stated that the order does not have a material impact on the entity.
Business Update
Neutral
2026-10-31 15:41
Concall Schedule
Concall Date: November 06, 2026
Concall Time: 05:00 PM IST
Governance
Neutral
2026-10-30 18:24
- Board Meeting scheduled on Friday, November 06, 2026
- Purpose: Consider and approve Unaudited Financial Results for Q2/H1 ended September 30, 2026
- Trading window remains closed until 48 hours after declaration of results
Routine
Neutral
2026-10-19 10:43
- Supriya Lifescience updated that the judicial proceedings matter has been admitted by the Hon'ble Supreme Court and listed for hearing.
- The Hon'ble Supreme Court directed that no coercive action shall be taken against the Directors, officers, or officials of the petitioner in the interim.
- The matter is sub judice and the company will continue to monitor and inform the stock exchanges of material developments.
Business Update
Positive
2026-10-13 14:10
- Supriya Lifescience Limited has received a voluntary ESG rating of 'CRISIL ESG 65' from CRISIL ESG Ratings & Analytics Limited.
- The rating places the company in the 'Strong' category.
- Disclosure made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015.
Governance
Neutral
2026-10-08 16:50
- Supriya Lifescience Ltd has filed a petition before the Hon’ble Supreme Court of India on October 8, 2026, in connection with ongoing judicial proceedings.
- This follows an earlier intimation dated September 23, 2026, regarding an order received from the Hon’ble High Court.
- The matter is currently sub judice and pending consideration.
Routine
Neutral
2026-09-28 15:33
- Trading window closed from October 01, 2026 for designated persons and insiders.
- Reopens 48 hours after declaration of Unaudited Financial Results for quarter and half year ending September 30, 2026.
- Board meeting date to be intimated in due course.
Governance
Neutral
2026-09-25 22:06
- Supriya Lifescience Limited held its 18th Annual General Meeting (AGM) on September 24, 2026, through Video Conferencing.
- All five ordinary resolutions, including the adoption of financial statements, declaration of final dividend of Re. 1.00 per share, and re-appointment of directors, were passed with the requisite majority.
Governance
Positive
2026-09-25 22:00
- Supriya Lifescience Ltd held its 18th Annual General Meeting (AGM) on September 24, 2026.
- All five resolutions, including the adoption of financial statements, declaration of a final dividend of Re. 1.00 per share, and re-appointment of directors, were passed with the requisite majority.
Business Update
Negative
2026-09-23 11:33
CRITICAL RED FLAG DETECTED
- The Hon'ble High Court of Bombay allowed the provisional release of a 200 kg consignment of Ketamine Hydrochloride, subject to a deposit of ₹72 lakh within one week.
- Adjudication and criminal proceedings related to the matter will continue in accordance with law.
Business Update
Neutral
2026-09-20 23:41
- Concall Schedule
- Concall Date: September 25, 2026
- Concall Time: 11:00 AM - 12:00 Noon.
Business Update
Neutral
2026-09-11 16:48
- Concall Schedule
- Concall Date: September 17, 2026
- Concall Time: 11:00 AM – 12:00 NOON
Governance
Neutral
2026-09-02 18:26
- Supriya Lifescience Limited will hold its 18th Annual General Meeting (AGM) on Thursday, September 24, 2026, at 3:00 P.M. (IST) via Video Conferencing / Other Audio Visual Means.
- The Annual Report for the financial year 2025-26 and the AGM notice are available on the company's website and stock exchange websites.
Business Update
Negative
2026-09-02 17:35
CRITICAL RED FLAG DETECTED
- Update on judicial proceedings involving the General Manager – Sales & Marketing.
- The matter remains sub judice with no new developments or court orders since August 2026.
- Company will continue to monitor and inform exchanges.
Governance
Neutral
2026-09-01 20:09
- Notice of the 18th Annual General Meeting (AGM) to be held on Thursday, September 24, 2026, at 03:00 p.m. (IST) via Video Conferencing/Other Audio Visual Means.
- The Annual Report for the financial year 2025-26, including the Business Responsibility and Sustainability Report, has been submitted.
Financials
Positive
2026-08-26 17:31
- Final dividend of Re. 1.00 per equity share for FY 2025-26 recommended by the Board.
- Annual General Meeting (AGM) scheduled for Thursday, September 24, 2026, at 3:00 p.m. (IST).
- Record Date for determining dividend entitlement is Friday, September 4, 2026.
Governance
Neutral
2026-08-22 13:08
- Outcome of postal ballot for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel for a term of three (3) consecutive years (May 26, 2026, to May 25, 2029).
- The resolution was passed with the requisite majority, with 99.69% of the total valid votes cast in favour.
Governance
Neutral
2026-08-22 13:06
- Supriya Lifescience Ltd. announced the voting results for the postal ballot conducted via remote e-voting.
- The resolution for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel for a term of three consecutive years (May 26, 2026, to May 25, 2029) was passed with 99.69% votes in favor.
Business Update
Negative
2026-08-18 16:40
CRITICAL RED FLAG DETECTED
- Q1 FY27 Revenue ₹190Cr vs Q1 FY26 ₹145Cr (▲31% YoY)
- EBITDA ₹47Cr vs ₹52Cr (▼8.1% YoY)
- PAT ₹24Cr vs ₹35Cr (▼31.4% YoY)
- EBITDA Margin 25% (Q1 FY27) vs 35.9% (Q1 FY26), impacted by ₹35Cr deferred sales due to water shortages and ₹8Cr higher power costs.
- Company maintains FY27 revenue guidance of ₹1,000Cr and EBITDA margin guidance of 33-35%, expecting recovery in subsequent quarters.
- Launched two new anesthetic liquid inhalation products in Q2 FY27; two ADHD products and contrast media expected in pipeline/H2 FY27.
- Progressing on CMO/CDMO opportunities; Phase-1 of Patalganga facility CapEx is around ₹200Cr.
- Acknowledged a customs issue for a specific consignment due to a "two-day technical lapse," with a general manager in judicial custody, but expects regularization. Water issue is resolved for Q2.
Business Update
Neutral
2026-08-14 17:23
- Audio recording of the Earnings Call held on August 14, 2026, discussing operational and financial performance for the quarter ended June 30, 2026, is available on the company's website.
Financials
Negative
2026-08-13 23:32
- Q1 FY27 Consolidated Revenue ₹189.75 Cr vs ₹145.07 Cr (▲30.8% YoY)
- EBITDA ₹47.46 Cr vs ₹51.70 Cr (▼8.2% YoY)
- PAT ₹24.04 Cr vs ₹34.79 Cr (▼30.9% YoY)
- EBITDA Margin 25.0% vs 35.6% (▼1060 bps)
Financials
Negative
2026-08-13 19:34
- Q1 FY27 Revenue from Operations ₹189.75 Cr vs ₹145.07 Cr (▲30.8% YoY)
- EBITDA ₹47.46 Cr vs ₹51.70 Cr (▼8.2% YoY)
- PAT ₹24.04 Cr vs ₹34.79 Cr (▼30.9% YoY)
- EBITDA Margin 25.0% vs 35.6% (▼1063 bps)
Financials
Negative
2026-08-13 18:50
- Q1 FY27 Standalone Revenue ₹189.75Cr vs ₹145.07Cr (▲30.79% YoY)
- EBITDA ₹47.46Cr vs ₹51.70Cr (▼8.21% YoY)
- PAT ₹24.04Cr vs ₹34.79Cr (▼30.89% YoY)
- EBITDA Margin 25.01% vs 35.64% (▼1063bps)
Financials
Negative
2026-08-13 18:40
- Q1 FY27 Standalone Revenue ₹189.75Cr vs ₹145.07Cr (▲30.79% YoY)
- EBITDA ₹50.11Cr vs ₹54.38Cr (▼7.85% YoY)
- PAT ₹24.04Cr vs ₹34.79Cr (▼30.90% YoY)
- EBITDA Margin 26.41% vs 37.48% (▼1107bps)
Business Update
Neutral
2026-08-10 21:46
- Concall Schedule
- Concall Date: Friday, August 14, 2026
- Concall Time: 11:00 A.M. IST
Governance
Neutral
2026-08-06 18:26
- Board meeting scheduled for August 13, 2026.
- Purpose: To consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026.
- Trading window for insiders closed from July 1, 2026, until 48 hours after results declaration on August 13, 2026.
Governance
Neutral
2026-07-21 16:54
- Company to seek shareholder approval via postal ballot for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and KMP for three years from May 26, 2026, to May 25, 2029.
- E-voting period: July 23, 2026 (9:00 a.m. IST) to August 21, 2026 (5:00 p.m. IST).
Business Update
Negative
2026-07-04 05:21
CRITICAL RED FLAG DETECTED
- Supriya Lifescience intimated about judicial proceedings against Mr. Sreekant Sreedharan, General Manager, Sales & Marketing.
- He is under judicial detention until July 17, 2026, following an investigation by the Customs Department under the NDPS Act for a procedural lapse.
- The company states no material impact on operations, financial position, or governance is expected.
Financials
Positive
2026-06-23 17:26
- Board recommended a final dividend of Re. 1.00 (50%) per equity share for FY 2025-26, subject to shareholder approval at the AGM.
- Dividends are taxable in shareholders' hands, and the company will deduct TDS.
- Shareholders need to submit tax-related documents by July 15, 2026, for appropriate TDS.
Routine
Neutral
2026-06-20 16:57
- Trading window closed from July 01, 2026, until 48 hours post-Q1 FY27 unaudited financial results declaration for the quarter ended June 30, 2026.
- This is in compliance with SEBI Insider Trading Regulations.
Business Update
Neutral
2026-06-15 12:42
- Concall Schedule
- Concall Date: June 18, 2026
- Concall Time: 02:00 PM - 03:00 PM
Routine
Neutral
2026-06-09 17:42
New Filing detected. See link for details.
Business Update
Positive
2026-06-02 16:14
- Reiterated FY27 guidance of approximately 20% annual revenue growth and EBITDA margin of 33-35%.
- On track to achieve INR 1,000 crores revenue milestone by FY27.
- Lote facility received USFDA Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) classification, with only one minor observation.
- Patalganga land clearances secured; Phase 1 groundbreaking in FY27 with planned capex of INR 200 crores for two API/intermediate and two formulation blocks.
- Scheduled annual maintenance shutdown in Q2 FY27 (August) for older blocks A&D, impacting quarterly linearity of growth.
- R&D investments doubled, focusing on new APIs, CMO/CDMO/CRO, and formulations R&D.
- Ambernath facility expected to start revenue contribution in FY27, with EU audit scheduled for H2 FY27. Full impact expected in 3-4 years.
Routine
Neutral
2026-05-30 14:41
Supriya Lifescience Ltd. submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as required by Regulation 24A of SEBI (LODR) Regulations, 2015. The report, issued by M/s. DSM & Associates, confirmed that the company fully complied with all applicable SEBI regulations and Secretarial Standards, with no non-compliances or deviations observed during the review period.
Business Update
Neutral
2026-05-28 16:07
Supriya Lifescience Limited announced that the audio recording of its Earnings Call, held on May 28, 2026, discussing the operational and financial performance for the quarter and year ended March 31, 2026, is now available on the company's website.
Financials
Positive
2026-05-28 09:15
Supriya Lifescience Limited reported Q4 FY26 consolidated results: Revenue ₹276.53Cr vs ₹184.11Cr (▲50.20% YoY), EBITDA ₹97.62Cr vs ₹67.58Cr (▲44.45% YoY), PAT ₹74.23Cr vs ₹50.37Cr (▲47.37% YoY). EBITDA Margin was 35.3% vs 36.7% (▼140bps). The company delivered strong performance with revenue growth driven by the anesthetic segment and improved capacity utilization.
Financials
Positive
2026-05-27 18:57
Supriya Lifescience Ltd. reported Standalone Revenue of ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA of ₹97.62 Cr vs ₹67.59 Cr (▲44.43% YoY), and PAT of ₹74.23 Cr vs ₹50.38 Cr (▲47.36% YoY) for the quarter ended March 31, 2026. EBITDA Margin was 35.30% vs 36.71% (▼141bps). The Board recommended a final dividend of ₹1.00 per equity share (50% on face value of ₹2/- each), subject to shareholder approval.
Financials
Positive
2026-05-27 18:44
Standalone Revenue ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA ₹97.62 Cr vs ₹67.59 Cr (▲44.44% YoY), PAT ₹74.23 Cr vs ₹50.38 Cr (▲47.35% YoY). EBITDA Margin 35.29% vs 36.71% (▼142 bps). The board also recommended a final dividend of Re. 1.00 per equity share for the financial year ended March 31, 2026.
Financials
Positive
2026-05-27 18:35
Standalone Revenue ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA ₹97.62 Cr vs ₹67.59 Cr (▲44.43% YoY), PAT ₹74.23 Cr vs ₹50.38 Cr (▲47.34% YoY). EBITDA Margin 35.29% vs 36.71% (▼142bps). The company also recommended a final dividend of Re. 1.00 per equity share.